Intrarosa (Prasterone Vaginal DHEA) and Pediatric Transition to Adult Care: What Families Need to Know

Why Prasterone Vaginal DHEA Has No Role in Children Under 12

Intrarosa is categorically not a pediatric drug. Full stop. The FDA granted approval in November 2016 specifically for post-menopausal women experiencing moderate to severe dyspareunia as a symptom of vulvovaginal atrophy (VVA), a condition driven by estrogen deficiency that does not exist in healthy pre-pubertal or reproductive-age girls 1.

The Physiology Gap Between a Pre-Pubertal Girl and a Menopausal Woman

Before puberty, a girl's ovaries produce minimal sex steroids. Adrenal DHEA secretion begins rising around age 6 to 8, a process called adrenarche, but circulating DHEA-S levels in girls under 12 are low and the vaginal epithelium is appropriately thin and unstimulated. That thinness is normal. It is not atrophy in the clinical sense, because atrophy implies loss of a previously estrogenized state.

In a post-menopausal woman, estrogen withdrawal causes measurable changes: vaginal pH rises above 5.0, superficial epithelial cells decrease, and submucosal collagen thins 2. Prasterone works by serving as a local precursor that vaginal cells convert to estradiol and testosterone via intracrinology, restoring the tissue toward its pre-menopausal state 3.

Applying that same mechanism to a pre-pubertal girl would mean introducing exogenous sex steroid precursors into tissue that has never been hormonally primed. The risks, though not formally studied because no ethical trial could be designed this way, include premature thelarche, accelerated bone age, and disruption of the hypothalamic-pituitary-gonadal axis. There is no clinical scenario in which a child under 12 should receive vaginal DHEA.

What the FDA Label Says

The prescribing information for Intrarosa carries no pediatric dosing section because no studies have been conducted in the pediatric population 1. The label states the drug is indicated for post-menopausal women. Pediatric safety and effectiveness have not been established. Using it off-label in a child would represent a significant deviation from evidence-based care and would expose both the patient and the prescriber to serious risk.

When Does Prasterone Become Relevant in the Transition from Pediatric to Adult Care?

The transition to adult gynecologic care is, for most girls, a routine milestone around age 18. But for a specific subset of young women, prasterone or other vaginal estrogen treatments become relevant much earlier. These are young women with conditions that produce premature estrogen deficiency.

Premature Ovarian Insufficiency (POI)

Premature ovarian insufficiency, defined as loss of normal ovarian function before age 40, affects approximately 1 in 100 women by age 40 and a smaller but clinically important fraction in the teenage years 4. Causes in adolescents include Turner syndrome, fragile X premutation carrier status, autoimmune oophoritis, and gonadotoxic chemotherapy or radiation.

A teenager with POI who does not receive hormone replacement will develop hypoestrogenic vaginal changes that are biologically identical to those in a post-menopausal woman. Once she transitions to adult care and is sexually active, she may develop dyspareunia and vaginal dryness that systemic hormone therapy alone does not fully resolve. At that point, adding a local vaginal therapy including vaginal DHEA becomes a reasonable clinical option, discussed under the supervision of an adult reproductive endocrinologist or menopause-certified clinician.

ACOG Committee Opinion 698 specifically addresses care for adolescents with POI and emphasizes the importance of comprehensive hormone replacement, including attention to genitourinary health, as these young women move into adult care 5.

Adolescents After Cancer Treatment

Girls who receive pelvic radiation or alkylating chemotherapy for childhood cancers face a high rate of gonadal insufficiency. The Children's Oncology Group long-term follow-up guidelines, updated regularly, flag genitourinary late effects as a priority concern for female survivors 6. A young woman transitioning from pediatric oncology to adult care may arrive at an adult gynecologist with years of untreated vaginal atrophy.

In that context, the adult clinician should assess vaginal health using the validated Vaginal Maturation Index and consider local therapy. Vaginal DHEA is one option, alongside vaginal estradiol cream, vaginal estradiol tablets, or the vaginal estradiol ring. The choice depends on whether the underlying malignancy was hormone-sensitive, the patient's comfort with vaginal insertion, and her contraceptive needs.

Gender-Affirming Care and Assigned-Female-at-Birth Adolescents

Adolescents assigned female at birth who use testosterone for gender-affirming hormone therapy develop vaginal atrophy due to androgen-dominant suppression of estrogen. This is a recognized and frequently under-treated condition. Some clinicians use low-dose vaginal estrogen in this population, and there is emerging interest in vaginal DHEA as an alternative because its local androgen metabolites may be acceptable to transmasculine patients who want to avoid systemic estrogen exposure 7.

This is an area where evidence is thin and largely extrapolated from adult studies. Any use in minors requires careful multidisciplinary consent and falls well outside any approved indication.

Sex-Specific Physiology of DHEA Across the Female Life Span

DHEA and its sulfated form DHEA-S follow a distinct trajectory across a woman's life. Understanding this arc is essential for contextualizing when prasterone becomes clinically meaningful.

Childhood Through Adrenarche (Ages 6 to 12)

Adrenal DHEA-S production begins rising around age 6 and continues through the early teens. By age 10, mean serum DHEA-S in girls is roughly 40 to 130 mcg/dL, depending on pubertal stage 8. This is adrenal in origin, not ovarian, and does not drive genital estrogenization. The vaginal epithelium at this stage is appropriately thin and unstimulated.

Reproductive Years (Ages 13 to 45, approximately)

During the reproductive years, DHEA-S peaks in the mid-twenties at roughly 200 to 350 mcg/dL in most women, then declines gradually 8. The vagina is well estrogenized. Prasterone has no indication in this life stage, and using a vaginal sex-steroid precursor in a reproductive-age woman without a specific diagnosed deficiency state would be inappropriate and potentially new to her hormonal milieu.

Perimenopause and Post-Menopause

DHEA-S continues declining through the perimenopausal years. After menopause, both ovarian and adrenal sex steroid production fall substantially. The vaginal epithelium loses its estrogen supply. In post-menopausal women, prasterone 6.5 mg nightly has been shown in the phase III AMETHYSTE and SERENADE trials to significantly increase the proportion of superficial vaginal cells, reduce vaginal pH, and reduce the severity of dyspareunia versus placebo 3 9.

Pregnancy, Lactation, and Contraception: Required Safety Information

Prasterone vaginal DHEA is contraindicated in pregnancy. This must be stated clearly to any young woman who is prescribed this drug after transitioning to adult care.

Pregnancy

DHEA is a steroid hormone precursor. Administering exogenous DHEA vaginally during pregnancy could theoretically expose the fetus to androgenic metabolites. There are no adequate and well-controlled studies of prasterone in pregnant women 1. Animal reproductive toxicology data are not fully predictive of human outcomes. The prescribing information advises that Intrarosa should not be used during pregnancy, and this is consistent with the general principle of avoiding exogenous sex steroid precursors during gestation.

For a young woman with POI transitioning to adult care who has any retained ovarian function or who is pursuing fertility treatment, a pregnancy test before initiating prasterone is appropriate, and the drug should be stopped if pregnancy is confirmed or suspected.

Lactation

It is not known whether prasterone or its estrogen and androgen metabolites are excreted in human breast milk. The FDA label does not support use during breastfeeding 1. The developmental and health benefits of breastfeeding should be weighed against the mother's clinical need, and this conversation should happen with her adult care provider. A post-menopausal woman, the primary indicated population, is not breastfeeding. A young woman with POI who has delivered a pregnancy via donor egg, however, might be lactating, and this scenario does arise in adult transition care.

Contraception

Because prasterone converts locally to estradiol and testosterone, there is a theoretical concern about systemic absorption and effects on a developing embryo if conception were to occur during use. Young women using vaginal DHEA who retain any ovarian function (possible in early POI) should use reliable contraception. The drug itself is not a contraceptive. The prescribing information does not quantify the teratogenic risk numerically, but the general principle of avoiding unnecessary sex steroid exposure in the first trimester applies 10.

Who This Drug Is Right For and Who It Is Not Right For, by Life Stage

This framework is designed to help clinicians and patients think through prasterone candidacy across the life span as a young woman moves from pediatric to adult care.

Not Appropriate

• Girls under 12 under any circumstances.
• Girls aged 12 to 17 with no diagnosed estrogen deficiency state. The vaginal epithelium is appropriately estrogenized during puberty and the reproductive years, and there is no indication for prasterone.
• Pregnant women or women trying to conceive without discussion of risks.
• Women with undiagnosed vaginal bleeding, as required by the label 1.
• Women with known or suspected estrogen-dependent neoplasia. The local-only estrogen exposure from vaginal DHEA is generally considered low systemic risk, but this requires an individualized conversation with an oncologist for hormone-sensitive cancer survivors.

Potentially Appropriate After Transition to Adult Care

• Young women aged 18 and older with confirmed POI who have genitourinary symptoms not fully resolved by systemic hormone therapy.
• Female survivors of childhood cancer with documented ovarian failure and symptomatic vaginal atrophy, provided their original malignancy was not hormone-sensitive.
• Post-menopausal women of any age (natural or surgical menopause) with moderate to severe dyspareunia due to VVA, which is the primary approved indication.
• Perimenopausal women with predominantly genitourinary symptoms, discussed with a clinician, though the trial evidence base is stronger in confirmed post-menopausal populations 3.

Planning the Transition: A Practical Clinical Checklist

Moving from a pediatric specialist to adult women's-health care is not a single appointment. For a young woman who may eventually need vaginal DHEA or related treatments, the transition should cover several areas.

Gynecologic History and Baseline Assessment

The adult clinician receiving a young woman from pediatric care should document: age at menarche (or confirmed amenorrhea/POI), hormone replacement history, any prior vaginal or pelvic symptoms, and the young woman's own description of her genitourinary experience. Vaginal symptoms are frequently underreported in adolescents because they assume discomfort is normal or feel uncomfortable raising the topic.

A structured genitourinary symptom screen using the Genitourinary Syndrome of Menopause (GSM) symptom questionnaire is a useful starting point even in younger women with POI or post-cancer ovarian failure 11.

Hormone Level Review

Before considering any vaginal sex steroid treatment, obtain: FSH, LH, estradiol, DHEA-S, testosterone total and free. In a young woman with POI, FSH above 40 IU/L on two measurements 4 weeks apart, combined with amenorrhea for 3 or more months, confirms the diagnosis 12. Once estrogen deficiency is confirmed, the conversation about local versus systemic therapy can begin.

Fertility Counseling

Young women with POI transitioning to adult care must receive explicit fertility counseling. Roughly 5 to 10 percent of women with confirmed POI will spontaneously conceive 12, so treating all of them as absolutely infertile is wrong. Any woman who wants to preserve the possibility of pregnancy should have that documented and should understand that stopping vaginal DHEA is the correct step if pregnancy occurs or is suspected.

The Menopause Society 2023 position statement on genitourinary syndrome of menopause recommends that "all women experiencing GSM symptoms be offered treatment," and this principle extends to young women with medically induced menopause 13.

Bone Health Review

Estrogen deficiency at any age accelerates bone loss. Young women with POI who reach adult care without adequate hormone replacement may already have reduced bone mineral density. A DXA scan is recommended at the time of POI diagnosis or transition to adult care in this population 14. Vaginal DHEA alone does not provide meaningful systemic estrogen levels sufficient to protect bone. Systemic estrogen or hormone therapy is necessary for skeletal protection in women with estrogen deficiency, and vaginal DHEA serves as an add-on for local genitourinary symptoms rather than a replacement for systemic treatment.

The Evidence Base: What Is Studied and What Is Extrapolated

The honest answer about evidence in young women is that almost everything specific to this population is extrapolated.

The phase III trials of prasterone, including the AMETHYSTE trial published in Menopause in 2016 and the follow-up 52-week safety data published in 2019 9, enrolled post-menopausal women with a mean age in the mid-to-late 50s. No adolescents or young adults with POI were enrolled. The efficacy data showing a statistically significant reduction in dyspareunia scores and increase in Vaginal Maturation Index values come entirely from this post-menopausal population 3.

Applying these findings to a 22-year-old with Turner syndrome and surgical gonadal failure is a reasonable clinical extrapolation based on shared pathophysiology, but it is extrapolation. Clinicians should say this explicitly to their patients and document it in the chart.

Women have been historically under-represented in clinical trials of genitourinary treatments, and young women with estrogen deficiency due to POI are among the most under-studied subgroups in all of gynecology. This is an area where research is genuinely needed, and patients should know that when a clinician recommends vaginal DHEA for POI-related GSM, the recommendation is based on biological plausibility and adult trial data, not pediatric or young-adult trial data.

Dosing, Administration, and Monitoring in Adult Care

Once a young woman with a valid indication transitions to adult care and a shared decision is made to use prasterone, the dosing and administration are the same as for any adult patient.

The approved dose is one prasterone 6.5 mg vaginal insert placed in the vagina once nightly using the supplied single-use applicator 1. There is no dose titration and no need to cycle the drug around a menstrual period, because women using it for POI or surgical menopause are typically amenorrheic.

Serum DHEA-S, estradiol, and testosterone levels should be checked at baseline and at 3 months in young women, given that their baseline hormone levels differ from those of older post-menopausal women and the target range is less well established in this population. The AMETHYSTE trial showed that systemic estradiol and testosterone rose minimally after nightly vaginal DHEA use and remained within the normal post-menopausal reference range in the enrolled population 3. Whether those same systemic exposure parameters apply to a 20-year-old with POI, whose tissues may absorb and metabolize the drug differently, has not been directly studied.

Response is typically assessed at 3 months using symptom scores and repeat Vaginal Maturation Index if available. If the patient has no symptomatic benefit after 12 weeks of nightly use, reassess the diagnosis and consider switching to a different local therapy.